Sep 09, 2021 / 12:45PM GMT
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity Analyst
Welcome, everyone, to day 1 of the Morgan Stanley Healthcare Conference. I'm Drew Ranieri, one of the medical device analysts here. It's my pleasure to have Chris Simon, President and Chief Executive Officer of Haemonetics with us here today. And there's a significant amount to talk about.
But before we jump into it, just a quick disclaimer. But for important disclosures, please see the Morgan Stanley research disclosure website at morganstaley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep.
But Chris, thanks for being here today. I really appreciate it for -- and thank you for your time.
Questions and Answers:
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity AnalystAnd I just want to start off this morning maybe on the Plasma business and kind of where recovery stands. So recovery in plasma collection continues to be kind of -- continues to lag, especially in your first quarter.